Abstract
Obesity and its related metabolic diseases, including type 2 diabetes, are associated with alterations in the circulating levels of various peptides. These include the adipocytokines (peptides released by adipocytes which circulate, such as leptin, adiponectin and resistin), and other peptides whose levels are altered in association with obesity (such as ghrelin, neuropeptide Y, interleukin-1β and tumour necrosis factor-α). While the primary action of these peptides is linked with the regulation and maintenance of energy balance and metabolism, many of them have also been shown to possess vasoactive, inflammatory and other properties that influence vascular biology, vascular physiology and atherogenesis. As such, they may form an important mechanistic link between obesity and cardiovascular disease. In this review, we will outline the vasoactive properties of adipocytokines and other obesity-related peptides. In particular, as pharmacotherapies suggested to achieve weight loss will alter the pathways associated with these peptides, such treatments might have either beneficial or deleterious effects on the incidence and progression of cardiovascular disease.
Keywords: Atherosclerosis, vascular biology, adipocytokines, obesity, leptin, adiponectin, resistin, neuropeptide Y
Current Vascular Pharmacology
Title: The Effects of Obesity-Related Peptides on the Vasculature
Volume: 4 Issue: 1
Author(s): Michael R. Skilton and David S. Celermajer
Affiliation:
Keywords: Atherosclerosis, vascular biology, adipocytokines, obesity, leptin, adiponectin, resistin, neuropeptide Y
Abstract: Obesity and its related metabolic diseases, including type 2 diabetes, are associated with alterations in the circulating levels of various peptides. These include the adipocytokines (peptides released by adipocytes which circulate, such as leptin, adiponectin and resistin), and other peptides whose levels are altered in association with obesity (such as ghrelin, neuropeptide Y, interleukin-1β and tumour necrosis factor-α). While the primary action of these peptides is linked with the regulation and maintenance of energy balance and metabolism, many of them have also been shown to possess vasoactive, inflammatory and other properties that influence vascular biology, vascular physiology and atherogenesis. As such, they may form an important mechanistic link between obesity and cardiovascular disease. In this review, we will outline the vasoactive properties of adipocytokines and other obesity-related peptides. In particular, as pharmacotherapies suggested to achieve weight loss will alter the pathways associated with these peptides, such treatments might have either beneficial or deleterious effects on the incidence and progression of cardiovascular disease.
Export Options
About this article
Cite this article as:
Skilton R. Michael and Celermajer S. David, The Effects of Obesity-Related Peptides on the Vasculature, Current Vascular Pharmacology 2006; 4(1) . https://dx.doi.org/10.2174/157016106775203135
DOI https://dx.doi.org/10.2174/157016106775203135 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Biosynthesis and Characterization of a Novel Fibrinolytic Alkaline Serine Protease from Newly Isolated <i>Bacillus flexus</i> BF12 for Biomedical Applications
Current Pharmaceutical Biotechnology Asymmetric Dimethylarginine: A Possible Link between Vascular Disease and Dementia
Current Alzheimer Research Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Improving Patient Compliance with Hypertension Treatment: Mission Possible?
Current Vascular Pharmacology The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design A Multi-Layer LSTM-Time-Density-Softmax (LDS) Approach for Protein Structure Prediction Using Deep Learning
Recent Advances in Computer Science and Communications The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
Current Alzheimer Research Self-care improvement after a pharmaceutical intervention in elderly type 2 diabetic patients
Current Diabetes Reviews The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Update on the Evidence of Statin Treatment to Reduce Plaque Vulnerability
Drug Metabolism Letters Association of Apolipoprotein E (ApoE) Polymorphism with Alzheimer's Disease in Chinese Population
Current Alzheimer Research